Alligator Bioscience (ATORX.ST)

Executive Summary

Alligator Bioscience AB is a clinical-stage Swedish biotech company focused on tumor-directed immuno-oncology. Its lead asset, mitazalimab (a CD40 agonist), is being evaluated in combination with chemotherapy for metastatic pancreatic ductal adenocarcinoma (Phase 1/2, NCT04888312) with primary completion expected in June 2026. The company is also advancing mitazalimab in a Phase 2/3 trial for biliary tract cancer (BTC, NCT07437287) recruiting from July 2026. Additionally, Alligator has an early-stage pipeline including ALG.APV-527 (Phase 1/2 solid tumor) and intratumoral mitazalimab plus nivolumab for breast cancer (Phase 1). With a market cap of ~$132M, Alligator represents a speculative investment hinging on mitazalimab's clinical data readouts and pipeline progression.

Upcoming Catalysts (preview)

• Q3 2026Mitazalimab pancreatic combo Phase 1/2 data readout45% success
• Q3 2026Mitazalimab biliary tract cancer Phase 2/3 trial initiation80% success
• TBDALG.APV-527 Phase 1/2 data update30% success